Mutant Kinases for Research and Lead Discovery

  • Therapeutically relevant—select from the most diverse collection of clinically relevant kinase mutants
  • Validation-qualified—all mutations confirmed by mass spectrometry and validated using control inhibitors
  • Ready-to-assay—most targets configured in Invitrogen’s fluorescent assay platforms
HGNCAlias

Select
Screen™
profiling
status

Clinical
Relevance		Drug
Resistance
ABL1 E255K 
YES
Chronic Myeloid Leukemia/ Gastrointestinal Stromal TumorGleevec® (Novartis)
ABL1 G250E 
YES
Chronic Myeloid Leukemia/ Gastrointestinal Stromal TumorGleevec® (Novartis)
ABL1 T315I 
YES
Chronic Myeloid Leukemia/ Gastrointestinal Stromal TumorGleevec® (Novartis)
ABL1 Y253F 
YES
Chronic Myeloid Leukemia/ Gastrointestinal Stromal TumorGleevec® (Novartis)
BRAF V599E 
YES
Melanoma/Papillary Thyroid Carcinoma 
EGFR L858RErbB1 L858R
YES
Non-Small Cell Lung Carcinoma 
EGFR L861QErbB1 L861Q
YES
Non-Small Cell Lung Carcinoma 
EGFR T790MErbB1 T790M
YES
Non-Small Cell Lung CarcinomaErlotinib (Tarceva®) and
Gefitinib (Iressa®)
EGFR T790M L858RErbB1 T790M L858R
NO
Non-Small Cell Lung Carcinoma 
FGFR3 K650E 
YES
Multiple Myeloma, Cervical Carcinoma, Bladder Carcinoma 
FLT3 D835Y 
YES
Acute Myeloid Leukemia 
JAK2 JH1 JH2 V617F 
NO
Myeloid Leukemia, Lymphoid Leukemia 
KIT T670IcKit T670I
YES
Gastrointestinal Stromal TumorGleevec® (Novartis)
KIT V654AcKit V654A
NO
Gastrointestinal Stromal TumorGleevec® (Novartis)
LRRK2 G2019S 
YES
Parkinson's disease 
MAP2K1, mutantMEK1
NO
  
MAP2K6, mutantMKK6, MEK6
NO
  
MET M1250T 
YES
Papillary Renal Carcinoma 
PDGFRA D842V 
YES
Gastrointestinal Stromal TumorGleevec® (Novartis)
PDGFRA T674I 
YES
Gastrointestinal stromal tumorGleevec® (Novartis)
RET Y791F 
YES
Thyroid carcinoma 
RET V804L 
YES
Thyroid carcinoma 
Select Language